Opinion

A space for healthcare professionals to freely share and discuss their opinions and experiences. Please contact us if you’d like to contribute.

WHAT'S ON THE HORIZON?

Opinion & insight from our Clinical Steering Group

Horizons, led by a team of experts from our Clinical Steering Group, is a series of scientific articles which take a deep dive into the emerging trends in the healthcare landscape, kickstarting a dialogue about how treatments and strategies should be best implemented for the benefit of patients. Click below to find out more.

What's on the horizon?

Marshall Pearce

How close are we to a disease-modifying treatment for Alzheimer’s?

Posted 4 months ago

Alzheimer’s disease is a snowballing problem, one that is currently without a convincing solution. The progressive decline in cognitive function seen in patients with Alzheimer’s disease is associated strongly with plaques formed of amyloid beta in the brain, creating neurofibrillary tangles and leading to neuronal destruction. While some treatments improve cognition in the short-term, current therapeutic options are unable to modify or slow the disease process.

Penny Staton

Improving non-alcoholic steatohepatitis care – is the finishing line in sight?

Posted 6 months ago

An intense race is going on right now in non-alcoholic steatohepatitis (NASH) research. A number of significant players within the pharmaceutical and biotechnology sectors are competing to develop the first major therapeutic advance in treatment for this neglected condition. But should we consider it more of a relay race? Could improved diagnosis, disease assessment and even combination therapy be the key to victory over this increasingly prevalent disease?

Marshall Pearce

Left ventricular assist devices – A viable therapeutic option for heart failure?

Posted 10 months ago

Alongside a pharmacological strategy to aid myocardial recovery, LVADs may prove to have a significant role to play in the ever-growing problem of heart failure. Although LVADs are not new onto the scene, the advance of technology – smaller, more efficient devices with better reliability and potentially transcutaneous power transfer – means we may be on the cusp of seeing many more deployed to tackle heart failure.

Marshall Pearce

Cancer immunotherapies

Posted 1 year ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 1 year ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Recent Articles

ECCMID 2018 ‒ Antibiotic resistance: an immediate and growing threat

This year’s ECCMID is hosting a large number of sessions discussing antibiotic resistance, an immediate and pressing issue that has been described as ‘one of the biggest threats to global health, food security, and development today'.

Alex Keen

Alex studied Biological Sciences at university before joining EPG Health in January 2017, where

...

ELCC 2018 ‒ Roundup of this year’s conference

At the recent ELCC, held from 11‒14 April 2018, several hundred abstracts were presented detailing the latest cutting-edge research in lung cancer treatment and care. Brief summaries of some of the key abstracts are found here.

Alex Keen

Alex studied Biological Sciences at university before joining EPG Health in January 2017, where

...

ILC 2018 – Targetable pathways in liver disease: from identification to clinical application

A number of studies from the speakers at this year's ILC Basic Science Seminar are discussed here, focusing on targetable pathways in liver disease, covering pathway identification, potential drug targets and their clinical application.

Alex Keen

Alex studied Biological Sciences at university before joining EPG Health in January 2017, where

...

ELCC 2018 ‒ And the Heine H. Hansen Award goes to…

Discover this year's Heine H. Hansen award winner, given to a scientific investigator who has made special, wide-reaching and significant contributions to lung cancer research and education, recognising their lifelong achievements.

Alex Keen

Alex studied Biological Sciences at university before joining EPG Health in January 2017, where

...

More articles

Dr Elizabeth Angier

What’s Allergy got to do with it?

Posted 10 months ago

Experiences of an allergy and immunology congress - a short blog (by a primary care physician).

Am Ang Zhang

Autism: Frances Tustin and Entrenchment!

Posted 2 years ago

Am Ang Zhang discusses his work with pioneering child psychotherapist Frances Tustin, and his observations of entrenchment in autistic children.

Robin Hewings

Diabetes Patients Must Be Better Educated About Their Condition

Posted 2 years ago

Not everyone is convinced that education courses help people look after their diabetes. And the GP I was chatting to a couple of months ago was one of them. He wasn’t sure they worked. People didn’t seem that interested and he wasn’t really sure what people would learn anyway.

Alastair Miller

What is Tropical Medicine?

Posted 2 years ago

At first sight this seems a question with an obvious response and not one that requires much debate in this blog. However, the answer may be more complex than it initially appears and may benefit from further exploration.

Hugh Harvey

Metrics Madness

Posted 2 years ago

You shouldn't judge a book by its cover. That much is true, but it's also common sense not to judge a book by measuring the whiteness of its pages, or the amount of hamsters you can place on it. So why do we measure the fabulous NHS with nonsense metrics?

David Warriner

What is Overdiagnosis?

Posted 2 years ago

Overdiagnosis is the diagnosis of disease that will cause neither morbidity nor mortality during a patient’s lifetime. Doctors are trained to listen, examine, test, diagnose and treat patients, but we are not warned of the possible dangers of “diseases”, the diagnosis of which will not benefit the patient and may also lead to harm. I would argue that the Hippocratic oath, in particular “Primum non nocere” (first, do no harm) should be at the forefront of every clinician’s mind when seeing patients.

Opinion archive